HC Wainwright

Analysts at H.C. Wainwright & Co. continue to see Ligand Pharmaceuticals Inc. (NASDAQ: LGND) as a "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares hit a four-month high on Wednesday following the release of strong sales by the company. HC Wainwright said underlying marketing dynamics give them confidence going forward. The firm reiterated its Buy rating and $60 price target. Analysts Andrew...

Shares of Cara Therapeutics Inc (NASDAQ: CARA) fell nearly 30 percent early Friday morning after the company released concerning top-line results from a phase 2B trial of its oral CR845 therapy for the treatment of pain associated with osteoarthritis of the hip or knee. But not all analysts are...

Axovant Sciences Ltd (NYSE: AXON) reported its fiscal fourth-quarter results on Tuesday, which helped push shares higher by more than 3.5 percent on Wednesday. Investors could potentially be rewarded with another upcoming catalyst in September with topline Phase 3 MINDSET results, analysts at HC...

Inovio Pharmaceuticals Inc (NASDAQ: INO) announced Thursday morning it has commenced a Phase III clinical program (called REVEAL) to evaluate the efficacy of its DNA-based immunotherapy, VGX-3100, to treat cervical dysplasia caused by human papillomavirus. Inovio's study will assess the efficacy...

Following Akebia Therapeutics Inc's (NASDAQ: AKBA) announcement of an expanded agreement with Otsuka (OTC: OTSKY) to develop and commercialize Vadadustat in Europe, China and Other Territories, HC Wainwright said in a note that the European partnership provides strong economics, removing any...

On March 28, Galectin Therapeutics Inc (NASDAQ: GALT) provided an update on the progress of its lead program, the Phase 2b trial of GR-MD-02 in Non-Alcoholic Steato-Hepatitis patients with cirrhosis (NASH-CX). Citing a “more positive view of the therapeutic potential of the mechanism of...

HC Wainwright has started coverage of The Medicines Company (NASDAQ: MDCO) with a Buy rating and $57 price target on the back of Phase 3-ready inclisiran (PCSK9si). Key Catalyst: Inclisiran Inclisiran is an RNAi therapeutic that inhibits synthesis of PCSK9 directly in the liver for potent and...

HC Wainwright has started coverage of vTv Therapeutics Inc (NASDAQ: VTVT) with a Buy rating and $13 price target on the potential success of its three late-stage drugs, especially the two diabetic compounds. In fact, the brokerage expects the diabetes compounds to be more likely to move the stock...

HC Wainwright has downgraded Mirna Therapeutics Inc (NASDAQ: MIRN) to Neutral from Buy as it awaits further steps from the company following the voluntary stop of the MRX34 trial, the company's investigational microRNA therapy for multiple cancers. Mirna stopped its Phase 1 study of MRX34 following...

HC Wainwright has initiated coverage of Proteon Therapeutics Inc (NASDAQ: PRTO) with a Buy rating and a price target of $18, representing a potential return of 105 percent. Proteon is developing a novel therapy to help prolong vascular access patency for dialysis patients. The company's lead...

HC Wainwright has started coverage of Oncomed Pharmaceuticals Inc (NASDAQ: OMED) shares with a Buy rating. The firm sees 68 percent potential upside for the pharmaceutical company on upcoming opt-in decisions for its lead drug candidates expected from three partners: Celgene Corporation (NASDAQ:...